Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 24th, 2018 | Posted by admin in Uncategorized

Researchers report that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.
Source: Care Giving Science Daily

You can follow any responses to this entry through the RSS 2.0 You can leave a response, or trackback.

Leave a Reply

Your email address will not be published. Required fields are marked *